Advanced Filters
noise

neoplasms Clinical Trials

A listing of neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,180 clinical trials

A Study of ASP1002 in Adults for Treatment of Solid Tumors

ASP1002 is a potential new treatment for people with certain solid tumors. Before ASP1002 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. This information will help find a suitable dose and check for potential medical problems from the …

18 years of age All Phase 1
Y Yongsheng Wang, Doctorate

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.

18 years of age All Phase 1

A Trial of HRS-6768 in Patients With Advanced Solid Tumors

The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.

18 - 80 years of age All Phase 1/2

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.

18 - 75 years of age All Phase 1

A Study of TYK-00540 in Adult Patients With Solid Tumors

The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.

18 years of age All Phase 1
J Juan L GCP Director

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors

This is a non-randomized,open-label,controlled multi-center Phase Ⅰ study to evaluate tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination with radiotherapy in patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors who have failed standard therapy or are unable to receive standard treatment.

18 - 75 years of age All Phase 1
W Weijing Zhang

A Study of HS-20124 in Patients with Advanced Solid Tumors

HS-20124 is a novel DAR-8 antibody-drug conjugate (ADC) targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor …

18 years of age All Phase 1
D Dezhi Clinical Operation derictor

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

18 years of age All Phase 1/2
J Jihui Hao, MD

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Objectives of Study:In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

18 years of age All Phase N/A
S Shujun Yang, Professor

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

This is a phase I/II study to evaluate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJB001 capsules in patients with advanced solid tumors, including dose escalation phase, dose expansion phase and cohort expansion phase.The study includes screening, treatment and follow-up periods. …

18 years of age All Phase 1/2

Simplify language using AI